{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:12:57Z","timestamp":1767611577232,"version":"build-2065373602"},"reference-count":28,"publisher":"Hogrefe Publishing Group","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vasa"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Summary: Background: To assess long-term patency rates, clinical outcomes, and device-related adverse events associated with the use of a dedicated woven nitinol venous stent following venoplasty to treat patients with symptomatic iliac and femoral vein obstruction. Material and methods: This single-center, single-arm, observational study consisted of 25 patients with iliofemoral vein obstructions caused by residual thrombosis, non-thrombotic compression, or post-thrombotic stenosis. Lesions were treated with the blueflow Venous Stent, a closed-cell stent made of woven strands of Nitinol wire. Primary outcome measures were primary patency and sustained clinical success at 3 months while secondary clinical measures included the revised Venous Clinical Severity Score (rVCSS), Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) classification, and the number of device-related adverse events through 60 months. Results: Primary patency was 94.7% and sustained clinical success was 76.5% at 3 months. Primary patency was 95.2% and 70% while sustained clinical success was 76.2% and 70% at 12 and 60 months. The mean rVCSS was 7.4 \u00b1 4.0 at baseline, 5.3 \u00b1 1.8 at 3 months, 4.6 \u00b1 1.4 at 12 months, and 2.6 \u00b1 0.9 at 60 months. CEAP classifications at baseline were predominantly C3 (52%) while 36%, 52%, and 40% of scores were C1\u2013C2 at 3, 12, and 60 months. One device-related adverse event (i.e., in-stent restenosis) was reported resulting in reintervention. There were three patient deaths: two from the progression of metastatic cancer and one from a bicycle accident. Conclusions: This exploratory study demonstrated a primary patency rate of 94.7% and a clinical success rate of 76.2% at 3 months. Patency was 70% with a 65% reduction in the mean rVCSS score from baseline at 5 years (\u22125.2). The blueflow Venous Stent performed adequately with no safety concerns when used for its intended indication.<\/jats:p>","DOI":"10.1024\/0301-1526\/a001191","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T04:54:33Z","timestamp":1742964873000},"page":"414-420","source":"Crossref","is-referenced-by-count":1,"title":["Long-term efficacy safety analysis of a woven nitinol venous stent for iliac vein obstruction"],"prefix":"10.1024","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2647-9876","authenticated-orcid":true,"given":"Michael K. W.","family":"Lichtenberg","sequence":"first","affiliation":[{"name":"Vascular Center, Klinikum Hochsauerland, Arnsberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Stahlhoff","sequence":"additional","affiliation":[{"name":"Vascular Center, Klinikum Hochsauerland, Arnsberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Mueller","sequence":"additional","affiliation":[{"name":"Vascular Center, Klinikum Hochsauerland, Arnsberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egor","family":"Nazarov","sequence":"additional","affiliation":[{"name":"Vascular Center, Klinikum Hochsauerland, Arnsberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Romano","sequence":"additional","affiliation":[{"name":"Vascular Center, Klinikum Hochsauerland, Arnsberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Stavroulakis","sequence":"additional","affiliation":[{"name":"Vascular Center, Klinikum Hochsauerland, Arnsberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","reference":[{"key":"c1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.002772"},{"key":"c2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2015.09.002"},{"key":"c3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2018.08.014"},{"key":"c4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00248-3"},{"key":"c5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615066"},{"key":"c6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2019.08.015"},{"key":"c7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2017.11.003"},{"key":"c8","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-021-02975-2"},{"key":"c9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008268"},{"key":"c10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.121.010960"},{"key":"c11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2022.12.066"},{"key":"c12","doi-asserted-by":"publisher","DOI":"10.1024\/0301-1526\/a000953"},{"key":"c13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2020.08.027"},{"key":"c14","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.21.04589-2"},{"key":"c15","doi-asserted-by":"publisher","DOI":"10.1024\/0301-1526\/a000763"},{"key":"c16","doi-asserted-by":"publisher","DOI":"10.1024\/0301-1526\/a000893"},{"key":"c17","doi-asserted-by":"publisher","DOI":"10.1024\/0301-1526\/a000772"},{"key":"c18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.009673"},{"key":"c19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2022.08.028"},{"key":"c20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2024.01.030"},{"key":"c21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2024.02.025"},{"issue":"2","key":"c22","first-page":"255","volume":"54","author":"O\u2019Sullivan GJ","year":"2013","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"c23","doi-asserted-by":"publisher","DOI":"10.1177\/0268355520946219"},{"key":"c24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2024.101816"},{"key":"c25","doi-asserted-by":"publisher","DOI":"10.15420\/ver.2021.19"},{"key":"c26","unstructured":"Davies A, Machin M. Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease (BEST). NCT05622500. Updated March 3, 2024. Accessed July 31, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05622500?cond=Deep%20venous%20disease&term=BEST&rank=1."},{"key":"c27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2023.06.013"},{"key":"c28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2021.12.024"}],"container-title":["Vasa"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/0301-1526\/a001191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T07:05:40Z","timestamp":1762153540000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/0301-1526\/a001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1024\/0301-1526\/a001191"],"URL":"https:\/\/doi.org\/10.1024\/0301-1526\/a001191","relation":{},"ISSN":["0301-1526","1664-2872"],"issn-type":[{"type":"print","value":"0301-1526"},{"type":"electronic","value":"1664-2872"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}